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Therapy for idiopathic membranous nephropathy: Tailoring the choice
by decision analysis. Two Italian controlled trials demonstrated that the
difference in remission rates obtained with six months of methyipred-
nisolone and chiorambucil (MP+Ch) compared to MP was smaller than
MP+Ch versus symptomatic therapy in the treatment of idiopathic
membranous nephropathy nephrotic syndrome (NS). A decision anal-
ysis was used to compare the three treatment strategies, assuming triple
probabilities and costs for MP+Ch complications compared to MP,
with no risk for supportive therapy, referring to an average 40-year-old
patient and using the quality-adjusted life expectancy year (QALY) as
the utility scale. With MP+Ch the difference in expected QALY was
7.2 years compared to supportive therapy, and 2.6 years compared to
MP. To offset the longer survival obtained with MP+Ch versus MP, it
was assumed that all patients treated with MP+Ch would undergo
either fatal (5% vs. 0.3% with MP) or non-fatal complications (95% vs.
15% with MP). This threshold denotes a great stability of the inequality
in the expected QALY. Consequently, treatment with MP or with
MP+Ch is justified if their side effects are considered to be a suitable
trade-off for a five or seven QALY, respectively, longer survival. Only
an absurd increase in the death rate with MP+Ch could offset the
difference.
The role of corticosteroid and cytotoxic agents for treating
idiopathic membranous nephropathy (IMN) is still controver-
sial. Two recent, controlled trials showed no benefit with
prednisone when given at high doses for two months [1] or at
moderate doses for six months [2]. On the other hand, an Italian
collaborative study reported more nephrotic syndrome (NS)
remissions and a better reciprocal of plasma creatinine in
patients treated with methyiprednisolone and chlorambucil
(MP+Ch) alternated every other month, for six months, than in
untreated controls [3]. More recently, another Italian controlled
study showed that MP+Ch for six months obtained more
remissions than MP alone [4]. The difference was significant at
one (58% vs. 26%), two (54% vs. 32%), and three (66% vs. 40%)
years, but not at four years (62% vs. 42%) where there was,
however, a sharp decrease in the statistical power because of
the reduction of patients at risk. It is interesting that the number
of remissions for patients treated with MP alone in the second
trial (38%) was greater than that observed in the untreated
Received for publication July 21, 1993
and in revised form October 27, 1993
Accepted for publication October 28, 1993
© 1994 by the International Society of Nephrology
patients in the first trial (23%), suggesting some advantage of
MP over symptomatic therapy.
The main problem in interpreting the long-term results of any
randomized treatment of IMN is the low statistical power of the
significance tests, which can obscure definite advantages of a
strategy. Therefore, the optimal regimen and the cost of obtain-
ing benefits from treatments are not yet clear, but cannot be
discounted. However, the complex decision of whether and
how to treat IMN might be elucidated by the use of decision
analysis to quantitatively incorporate life expectancy, quality of
life, and efficacy of therapy on both remission and progression
to renal failure (RF) and side effects [5, 6]. We therefore
reanalyzed by decision analysis the results of the two Italian
collaborative trials [3, 4] which have the advantage of having
been conducted by the same clinicians, sampled from the
identical geographical area and having recruited patients with
uniform criteria for selection.
Methods
Patients
We evaluated the outcome for a representative patient with
IMN and NS, who received supportive therapy, MP, or
MP+Ch, using results of the two Italian trials [3, 4] for a
decision analysis to select the optimal treatment strategy.
Characteristics of patients at enrollment are reported in Table
1. Patients of the MP+Ch group received at months 1, 3, and 5,
three cycles of treatment with MP, 1 g given intravenously on
three consecutive days followed by daily single morning oral
dose of 0.4 mg MP per kg of body weight for 27 days. Each
cycle was followed by one month of oral treatment with Ch at
0.2 mg per kg per day. The total duration of treatment was six
months. Patients of the MP group received 1 g of MP intrave-
nously on three consecutive days at the beginning of first, third,
and fifth month followed by an oral dose of 0.4 mg MP per kg
every other day for six months, except during the period of
intravenous administration.
Decision analysis
A decision tree was devised considering three therapeutic
strategies: supportive, MP, and MP+ Ch (Fig. 1, primary tree).
Calculations were made with the Decision Maker computer
program [71, using the structure and basic assumptions for
idiopathic NS discussed in detail by Kassirer [5] and Levey et
al [6]. The tree contained 28 nodes, including 1 decision node
1193
1194 Piccoli et at: Therapy for membranous nephropathy
Table 1. Characteristics of the patients at enrollment into the Italian
collaborative trials
First trial [3]
Supportive MP+Ch
Second t
MP+Ch
na! [4]
MP
Total, N 39 42 47 45
Age, years
median 42 43 47 46
range 16—74 15—70 14—64 14—65
Sex (MJF) 29/10 34/8 27/20 32/13
Months of disease
median 5 6 6 5
range 1—52 1—50 1—180 1—138
Plasma creatinine, mg/dl
mean 1.0 1.1 1.0 1.0
SD 0.3 0.2 0.3 0.3
Proteinunia, giday
mean 5.3 6.2 7.0 7.6
SD 2.8 3.0 4.1 4.2
Hypertension, N 12 8 14 15
Kidney biopsy findings, N
Stage of glomerular lesions
I—Il 30 32 29 27
1II—IV 9 10 18 18
Vascular lesions 8 9 8 8
Tubulointerstitial lesions 18 17 18 18
Treatment strategies included supportive, methylprednisolone (MP),
or methylprednisolone plus chiorambucil (MP+Ch).
and 27 chance nodes, and 64 branches, 37 of which are terminal
branches (Fig. 1).
Since the median age of patients with NS in the two trials and
in one reference tree [6] was 40 years, we used this age for the
average nephrotic patient in our decision analysis. Moreover,
since both the trials and the reference trees [5, 6] considered
patients with NS in whom serum creatinine concentrations
were lower than 150 mo1Iliter (1.7 mgldl) and 177 mol/liter
(2.0 mg/dl), respectively, a representative patient with normal
renal function was considered in our analysis.
First the expected utilities for each strategy were calculated
for a 40-year-old patient using the baseline values for branch
probabilities and outcome utilities. Second, the sensitivity and
threshold analyses [5, 6] were performed on assumptions for
risks and the trials' probabilities of outcomes. Finally, the
analysis was extended to representative 20- and 60-year-old
patients.
Baseline analysis
Probabilities of complications. Reported probabilities for the
complications of the NS were directly applied (0.3% for death
and 5% for non-fatal complications) [5, 6], and the rule estab-
lished by Kassirer and Levey was used in assigning probabili-
ties for complications of steroid treatment (estimated at 0.1%
for death and 5% for non-fatal complications) per course of
conventional treatment (125 mg prednisone every other day for
2 months, with tapering over an additional I or 2 months) [5, 6].
The probabilities were assigned on this premise, therefore,
following Italian protocols with MP or MP+Ch which were
based on a single immunosuppressive course; a patient received
the conventional steroid dose three times (about 12 vs. 4 g, for
70 kg of body weight, over 6 vs. 2 months). Therefore, in our
steroid treatment branches (Fig. 1) probabilities became 0.3%
for death and 15% for temporary morbidity due to steroid
treatment. However, compared to the conventional treatment,
a lower dosage (30mg for 70 to 80kg of body weight vs. 125 mg)
of oral steroid was given either every other day with the MP
treatment, or daily but every other month with the MP+Ch
treatment. It was also assumed [5, 6] that therapy was discon-
tinued if serious treatment-related complications occurred and
if complications occurred two to six months after beginning
therapy, so that patients still received some benefit from
treatment, even if it was eventually discontinued. Similarly,
complications from combination therapy (Fig. 1, third branch,
primary tree), may result in either death or temporary morbid-
ity. Since in the considered protocols [3, 4] patients developing
complications from Ch did not stop the MP treatment, they still
received some benefit from therapy. While much less than 15%
of patients were required to stop Ch due to side effects (gastric
intolerance, and severe leukopenia), with stable values reaching
9.5% for both trials (4 of 45 and 4 of 39, respectively), the
impact of morbidity was assumed to be triple for MP+Ch
compared to MP alone (that is 9 times the rate with the
conventional steroid treatment), namely 0.9% and 45% for fatal
and non-fatal complications, respectively.
Moreover, given the delayed response with both MP and
MP+ Ch (89% remission after the end of treatment [3, 8]), it was
assumed that treatment did not reduce the risk for early
complications of NS (infection, thromboembolism, vascular
collapse, and acute renal failure) [5, 6]. In the baseline analysis
we assumed equal probabilities for the short-term complica-
tions from NS for the three strategies, despite a longer cumu-
lative remission interval in MP+Ch compared to MP group, and
in both treatments compared to supportive strategy [3, 4, 8, 9].
In all strategies, values for the probabilities of subsequent
outcomes of NS, either remission from or progression to RF
(Fig. 1, branches of the 0 subtree), were derived from the two
trials [3, 4] (Table 2) considering three groups of results. The
data were divided into the following sets: the frequency of
events during the entire follow-up (that is, the number of
patients who had a first NS remission or a progression to RF at
some time-point of the follow-up) (set A); frequency of events
at the end of follow-up (the number of patients in remission or
with progression to RF at the last visit) (set B); and frequency
of events at the last visit of patients ending the fourth year of
follow-up (set C). Estimates for the probabilities in set C (Table
2) were taken from tables or derived from figures of the original
papers [3, 4]. The event, "progression to RF," in the original
papers was indicated by an increase in the plasma creatinine
concentration of 50% or more over baseline levels. For the
event NS remission, we separately considered the events
"complete" (restoration of normal protein excretion to less
than 200 mg!24 hr), or "at least partial," that is, complete or
partial remission (sustained reduction in proteinuria to between
200 mg and 2 g124 hr) [3—6]. We did not refer to a single
evaluation of these events, since individual readers can use
different criteria in evaluating the treatment's effect.
The same estimates of probabilities for outcomes were ex-
tended to the analysis of patients aged 20 and 60 years.
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Figure 1. The decision tree The tree Contains 28 nodes, including 1 decision node, 27 chance nodes, and 64 branches of which 37 are terminal
branches. The square node denotes the decision. The three branches emanating from it represent the three therapeutic strategies. Circular nodes
represent chance events that may follow each choice. Final outcomes are indicated by rectangles. Values for probabilities of chance events and
quality adjustments are given in the text and in the Appendix. In the supportive strategy (top branch), patients are not at risk for treatment
complications. In the steroid (middle branch) and steroid-alkylating strategies (third branch) patients are at risk for complications from treatment
(T subtree). Abbreviations are: NS, nephrotic syndrome; RF, renal failure; T, treatment subtree; N, nephrotic syndrome subtree; 0, outcome
subtree.
Assignment of utilities
Four outcomes of NS are considered relevant in the analysis
[5, 6] (Fig. 1): (1) early death, occurring during the first two
years, due to fatal complications either from NS or treatment;
(2) persistence of NS with subsequent development of RF; (3)
persistence of NS with maintenance of stable renal function; (4)
sustained remission of proteinuria within the first two years,
and maintenance of stable renal function thereafter.
In short, the quality-adjusted life expectancy year(s) (QALY)
was used as the utility scale [5, 6]. The resulting number of
QALY is the number of years at full health that would be valued
equivalently to the number of years of life as experienced. A
value for life expectancy (LE) of zero was assigned to deaths
that result from therapy and fatal complications from NS. If a
40-year-old patient on supportive therapy experiences sponta-
neous remission and has no serious complications due to NS,
the utility for this outcome was simply the age-adjusted LE, or
36.4 years [6, 10] because the penalty for all complications was
zero. In the analysis, the penalty adjustments (non-monetary
costs) for the quality of life were made by subtracting a fixed
amount of time for short-term complications (non-fatal compli-
cations from NS and treatment), and by reducing LE by a fixed
proportion for complications that produced sustained disability
(persistent NS and RF) (see Appendix for equations) [5, 6].
Monetary expense was not considered in the analysis.
The penalty for short-term non-fatal complications of NS was
fixed at two weeks (0.04 QALY) for all strategies [6]. The
impact of long-term complications of persistent NS were incor-
porated in the analysis by decreasing the quality of life in
patients with persistent NS by multiplying the time interval
over which the patient was nephrotic by 0.9 (Appendix) [5, 6].
For patients developing terminal RF and treated indefinitely
by dialysis, QALY was taken as the sum of the two intervals,
namely the survival until terminal renal failure (SRF = 10 years
for IMN) independent of age and unaltered by specific therapy,
and the LE in dialysis-treated renal failure (LERF =9.7 years)
[6, 11], dependent on age when terminal RF develops (that is, 50
years) and independent of whether specific treatment was given
for NS, both adjusted, when appropriate, for the quality of the
patient's life (Appendix).
No complication, and so no cost, was considered for support-
ive therapy.
STEROID
A
Non-fatal NS complicationNon-fatal treatment complication
Death1entdeL
lication DeathFatal NScomp
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Table 2. Outcome for a 40-year-old nephrotic patient with idiopathic membranous nephropathy who received supportive, MP, or
MP+Ch treatment
size
Probability of
xpected survival
QALY, yearsSample Remission Renal failure
E
Set SUP MP MP+Ch SUP MP MP+Ch SUP MP MP+Ch SUP MP MP+Ch
A 39 47 87 0.333 0.553 0.782 0.487 0.213 0.115 25.9 31.1 33.3
95% CI 0.19—0.50 0.40—0.70 0.68—0.86 0.32—0.65 0.11—0.36 0.06—0.20
A/CR 0.179 0.362 0.506 25.3 30.4 32.3
95% CI 0.08—0.34 0.23—0.52 0.40—0.62
B 39 47 87 0.231 0.383 0.644 0.487 0.213 0.115 25.5 30.5 32.8
95% CI 0.11—0.39 0.25—0.54 0.53—0.74 0.32—0.65 0.11-0.36 0.06—0.20
B/CR 0.051 0.213 0.345 24.8 29.8 31.7
95% CI 0.01—0.17 0.11—0.36 0.25—0.45
C 26 31 66 0.385 0.419 0.667 0.538 0.323 0.121 25.2 28.8 32.7
95% CI 0.20—0,59 0.25—0.61 0.54—0.78 0.33—0.73 0.17—0.51 0.05—0.23
C/CR 0.154 0.226 0.303 24.4 28.1 31.4
95% CI 0.04—0.35 0.10—0.41 0.20—0.43
Results of baseline analysis assume no costs for complications from supportive therapy, triple costs for MP strategy compared to the
conventional steroid treatment, and additional triple costs with MP + Ch compared to MP (that is, 9 times compared to the conventional steroid
treatment). Sets are: (A) set with frequencies of events over the entire follow-up period (that is, first NS remission or progression to RF at some
time-point); (B) set with frequencies of events at the end of follow-up (last visit); (C) set with frequencies at the last visit of patients ending the
fourth year of follow-up. Abbreviations are: (/CR) same sets, A, B, and C, considering only complete remission as remission; (SUP) supportive
therapy; (MP) methylprednisotone; (MP+Ch) methylprednisolone plus chiorambucil, results from both Italian trials [3, 4); (QALY) quality-
adjusted life expectancy year; (CI) confidence interval.
The quality-of-life adjustment for non-fatal complications
following MP treatment was performed by subtracting a fixed
amount of time (2 weeks = 0.04 QALY [6]), while costs for
MP+Ch strategy were assumed to be triple compared to MP
therapy (6 weeks = 0.12 QALY).
Sensitivity and threshold analyses
In formulating the baseline analysis, several assumptions
were made that biased the analysis both in favor of the
supportive strategy and against the MP+Ch strategy. On one
hand, deliberate biases were included to ensure that the advan-
tages of the most conservative approach were not overlooked.
Indeed, as in the reference trees [5, 6], supportive therapy was
considered a reference strategy with no cost for complications
from therapy and with the same rate of NS complications as MP
and MP+Ch strategies, despite longer exposure to persistent
NS. However, using these assumptions, the maximal expected
utility of supportive strategy for a best-case patient could be
calculated. On the other hand, assuming triple probabilities and
costs for MP+Ch complications compared to MP, the real
impact of more side effects was inflated with the most aggres-
sive, but possibly the most effective, combined therapy [3, 4,
12—191.
However, the structure of the Italian protocols permitted
analysis and varying of parameters within meaningful inequal-
ities centered on MP strategy, since the same course of steroid
was given in the MP and MP+Ch strategies. Therefore, first,
assumptions on efficacy and complications ensuing MP therapy
were varied to obtain equal expected utility as with supportive
therapy, and second, efficacy and costs for both supportive and
MP+Ch therapies were varied to obtain equal expected utility
values as with MP strategy. These values for parameters were
called "thresholds," namely values (if they existed) across
which no compared strategy was preferred [5, 6].
To take into account the phenomena of "close calls" or
"toss-ups" in the threshold analysis [20], six months of LE
(that is, 0.5 QALY, which was about 2% of the LE) was defined
as the minimal difference between expected utilities that would
seem important to a 40-year-old patient. Then the range of
probabilities that resulted in a difference in expected utilities
that was less than this minimal difference was calculated. Thus,
the decision was considered to be a toss-up if the probabilities
for either remission or progression to RF with a strategy fell
within the range corresponding to the minimal difference in LE.
In the sensitivity and threshold analyses, the impact on the
decision was tested by varying the following parameters: (a)
effect of better results with supportive therapy; (b) effect of the
high risk of MP therapy; (c) effect of worse results with MP; (d)
effect of the high risk of MP+Ch therapy; (e) effect of worse
results with MP+Ch therapy; (I) effect of NS duration on its
complications.
Extension to younger and older patients
The expected utility was calculated for 20-year-old and
60-year-old representative patients. The baseline assumptions
on probabilities and costs for complications, and the A, B, and
C data-sets for probabilities of NS remission and RF were the
same as for the 40-year-old patient. Only the LE and the LERF
of the patients were changed, being set at 56.3 and 15.0 years
for age 20 and at 22.3 and 5.0 for age 60 [5, 10, 11]. Values of
age-adjusted LE for Italians in the last two decades were close
to the assumptions of the analysis at 20, 40, and 60 years.
Results
Baseline analysis
Results of the baseline analysis are reported in Table 2. The
expected utilities (expected survival, QALY) for each strategy
were calculated using the three sets of probabilities for the
Piccoli et a!: Therapy for membranous nephropathy 1197
Table 3. Thresholds for probabilities and costs of the three treatment stratelies
Hypothesis Remission
Probability of
renal failure
Complications Costs for non-fatal
complications
QALY, yearsnon-fatal death
Set A
Better with SUP
vs. MP 0.64—0.67 0,17—0.19 0 0 0
vs. MP+Ch 0.78—0.81 0.03—0.06 0 0 0
Worse with MP vs. SUP 0,10—0.15 NF NF 0.16—0.17 32—35
Worse with MP+Ch
vs. SUP 0.18—0.22 NF NF 0.22—0.23 16—17
vs. MP 0.61-0.65 NF NF 0.06-0.08 4—7
Set B
Better with SUP
vs. MP 0.56—0.59 0.18—0.21 0 0 0
vs. MP+Ch 0.72—0.75 0.04—0.07 0 0 0
Worse with MP vs. SUP NF 0.49—0.52 NF 0.15—0.17 30—34
Worse with MP+Ch
vs. SUP NF NF NF 0.22-0.23 15—16
vs. MP 0.39—0,45 0.22—0.26 NF 0.07—0.08 5—6
Set C
Better with SUP
vs. MP 0.56—0.59 0.32—0.35 0 0 0
vs. MP+Ch 0.78—0.81 0,08—0.10 0 0 0
Worse with MP vs. SUP 0.14—0.18 0.52—0.55 NF 0.11—0.13 21—24
Worse with MP+Ch
vs. SUP NF NF NF 0.23-0.24 16-17
vs. MP 0.26-0.31 NF NF 0.12-0.13 8-9
Definitions of sets and abbreviations are in Table 2. NF means not found (by the one-way sensitivity and threshold analyses).
The "0" values for both probabilities and costs of complications following the supportive strategy, are not thresholds but fixed constraints in
favor of the supportive strategy.
outcomes (set A, entire follow-up; set B, at the end of follow-
up; set C, at least four years of follow-up). For each set, a
separate analysis was made considering NS remission as com-
plete remission.
Under the baseline assumptions of no cost for supportive
therapy, triple costs for MP compared to the conventional
steroid treatment, and an additional threefold increase in costs
for fatal and non-fatal complications with MP+Ch compared to
MP alone (that is, 9 times the costs following the conventional
steroid treatment), the preferred strategy in all data sets was
MP+Ch, considering either partial or complete remission (Ta-
ble 2). In particular, the difference in QALY with MP+Ch
compared to supportive strategy was more than seven years
(average 7.2, range 7.0 to 7.5), and more than 1.9 years (average
2.6, range 1.9 to 3.9) compared to MP strategy. The difference
in QALY with MP compared to supportive strategy was more
than 3.5 years (average 4.6, range 3.6 to 5.2).
In absolute terms, the best LE of a 40-year-old nephrotic
patient, which was 36.4 years, will decrease to an average of
25.2 QALY with supportive therapy, to 29.8 QALY with MP
alone and to 32.4 QALY with MP+Ch therapy. In other words,
following MP+Ch treatment, 64% LE can be recovered of
which 64% can also be obtained with MP treatment alone.
The patients' gender did not influence the expected utility for
neither supportive (LE 25.6 for males and 25.2 QALY for
females) nor the MP+Ch strategy (LE 32.6 for males and 33.2
QALY for females). Female gender was associated with better
expected utility following MP treatment (LE 33.5 for females
and 28.2 QALY for males). The influence of the level of
proteinuna at enrollment was evaluated with a cut-off value of
5 glday(in the range of 3.5 to 5.0 glday vs. > 5.0 g!day). The LE
was longer in the group with lower proteinuria levels, following
either the supportive (LE 25.8 vs. 24.7 QALY) or the MP+Ch
strategy (LE 34.3 vs. 31.6 QALY), while the reverse inequality
was obtained with MP (LE 29.4 vs. 31.4 QALY in patients with
both lower or higher proteinuria levels). Further analysis was
avoided due to the small sample size of these subgroups of
patients.
Sensitivity and threshold analyses
To determine if our conclusions were influenced either by
baseline assumptions or by a particular efficacy of therapy,
calculations were repeated as necessary for sensitivity and
threshold analyses. For simplicity, the results obtained consid-
ering the NS remission as at least partial remission are reported.
We considered the decision a "toss-up" if the LE between two
strategies differed by less than six months (0.5 QALY). The
ranges of threshold probabilities and costs within which the
difference in expected utilities of two strategies were less than
the LE minimal difference of six months (that is, the threshold
ranges within which the decision would be considered a toss-
up), are reported in Table 3.
Effect of better results with supportive therapy. The threshold
probabilities for NS remission, assuming better results with
supportive compared to MP strategies, were higher than the
upper 95% confidence limits with supportive therapy in the sets
A and B, but within the upper confidence limit in the set C
(Table 2). Under the hypothesis of better results with support-
ive compared to MP+Ch strategies, the threshold probabilities
for remission were higher than the upper 95% confidence limits
with supportive strategy in the three data sets.
The threshold probabilities for progression to RF, assuming
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better results with supportive compared to MP strategies, were
less than the lower 95% confidence limits with supportive
therapy in the data sets A and B, but within the confidence
interval in the set C (Table 2). Under the hypothesis of better
results with supportive compared to MP+Ch strategies, the
threshold probabilities for progression to renal failure were less
than the lower 95% confidence limits with supportive strategy in
the three data sets.
Thus, separately considering both outcomes (the NS remis-
sion and the progression to RF), and aiming to achieve the
expected survival of MP+Ch treatment with supportive treat-
ment, we had to assume a probability of remission with sup-
portive treatment in all data sets that was higher than the upper
95% confidence limit, or alternatively, a probability of progres-
sion to RF less than the lower 95% confidence limit observed
with supportive therapy. Similar inequalities were found in the
sets A and B to achieve the expected survival with MP.
Effect of high risk of steroid therapy. The threshold proba-
bility for death rate following MP compared to supportive
strategy was greater than 11% in the three sets, while the
threshold cost for non-fatal complications was more than 21
QALY (Table 3).
Effect of worse results with steroid (Table 3). To offset the
greater expected survival with MP compared to the supportive
therapy, the probability of NS remission with MP must be
decreased below the lower 95% confidence limits observed with
both MP and supportive therapy in sets A and C, and below any
threshold value in set B (no threshold value). Alternatively, the
probability of progression to RF must be increased in sets B and
C, not only above the upper 95% confidence limits observed
with MP, but also within the confidence intervals with support-
ive therapy. In the set A no threshold value was found (Table
2).
Effect of high risk of MP+ Ch therapy. The threshold proba-
bilities for death rate following MP+Ch therapy compared to
the supportive strategy were higher than 22% in the three data
sets (Table 3). In other words, to offset the 64% recovery in
expected survival with MP+Ch compared to supportive ther-
apy, a death rate higher than 22% with MP+ Ch was assumed,
compared to the baseline rate of 0% with supportive therapy.
No threshold probability was found for non-fatal complications
in any data set (that is, MP+Ch was still preferred to the
supportive strategy despite the assumption of 100% non-fatal
complications from MP+Ch treatment).
The threshold probabilities for death following MP+Ch com-
pared to MP strategy were higher than 6% in the three sets.
Thus, to offset the 36% gain in expected survival following
MP+Ch compared to MP treatment, a death rate higher than
6% with MP+Ch was assumed, compared to the baseline rate of
0.3% following MP treatment. There was no threshold proba-
bility for non-fatal complications in any data set.
The cost thresholds for non-fatal complications with MP+Ch
were higher than 16 QALY compared to the supportive strat-
egy, and higher than 4 QALY, compared to the MP strategy.
A more meaningful, clinically-applied combined threshold for
MP+Ch versus MP was found assuming that all patients treated
with MP+Ch would undergo either fatal (5% vs. 0.3% with MP
alone) or non-fatal complications (95% vs. 15% with MP alone),
and that costs for non-fatal complications are of the order of 1
QALY (range 0.4 to 2.9 QALY) versus 2 weeks (0.04 QALY)
with MP alone. In other words, to offset the advantage in
expected survival obtained with MP+Ch versus MP, risk ratios
were 17:1 for death rate, 6:1 for non-fatal complications, and
25:1 for costs in QALY for morbidity.
Effect of worse results with MP+Ch therapy (Table 3). The
threshold probabilities for NS remission with MP+Ch com-
pared to the supportive strategy, under the hypothesis of worse
results with MP+Ch treatment, were less of the lower 95%
confidence limits for both MP+Ch and MP strategies. More-
over, due to the low rate of progression to RF with MP+Ch, no
threshold was found for the probability of remission in the sets
B and C (that is, MP+Ch was still preferred despite the
assumption of no remission following MP+Ch), and a threshold
value close to the lower 95% confidence limit was observed
with the supportive strategy in the set A (Table 2). The
threshold probabilities for remission with MP+Ch compared to
the MP strategy were below the 95% confidence interval of the
MP+Ch treatment and within the confidence interval of MP in
the three sets (Table 2).
No threshold probabilities were found for the progression to
RF, assuming worse results with MP+Ch, compared to the
supportive strategy (that is, MP+Ch was still preferred to the
supportive strategy despite the assumption of 100% RF in
patients without remission). Assuming worse results with
MP+Ch compared to the MP strategy, no threshold probabili-
ties for progression to RF in sets A and C was found. In set B
the threshold value was higher than upper 95% confidence limit
of MP+Ch, but within the confidence interval of MP.
Effect of NS duration on its complications. The analysis was
carried out by weighing the probability of NS complications by
the ratio months with NS to months of follow-up (unpublished
data). The average values of the ratios were as follows: 0.73 for
supportive, 0.64 for MP, and 0.43 for MP+Ch strategy. There-
fore, probabilities for fatal and non-fatal NS complications were
multiplied by 7.3, 6.4, and 4.3 in the appropriate branches of the
decision tree (Fig. 1, N subtree).
The expected survivals were: 25.4 QALY for supportive
treatment, 30.6 QALY for MP, and 32.9 QALY for MP+Ch in
the set A; 25.0 QALY for the supportive, 29.9 QALY for MP,
and 32.4 QALY for MP+Ch strategy in the set B; and 24.7
QALY for the supportive, 28.3 QALY for the MP, and 32.4
QALY for MP+Ch strategy in the set C. Similar inequalities
were found by weighing both the probabilities and the costs of
NS complications (that is, using 0.73, 0.64, and 0.43 QALY
instead of 0.04 QALY).
Since these expected utilities differed from the baseline LE
by the order of the minimal difference of 0.5 QALY, the effect
of timing of NS complications was considered not significant.
Extension to younger and older patients
The expected utilities for 20- and 60-year-old representative
patients are reported in Table 4. Under the same baseline
assumptions for costs and complications as in the 40-year-old
patient, the preferred strategy in all data sets was MP+Ch,
considering either partial or complete remission.
In absolute terms, the best LE of a 20-year-old nephrotic
patient, which is 56.3 years, will decrease to an average of 36.5
QALY with supportive therapy, to 44.8 QALY with MP alone
and to 49.5 QALY with MP+Ch therapy. The difference in
QALY with MP+Ch was more than 12 years (average 13.0,
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Table 4. Outcome for a 20- and 60-year-old nephrotic patient with
membranous nephropathy who received supportive, MP, or MP+Ch
treatment
Set
Expected survivaI, QALY, years
Age 20 years Age 60 years
SUP MP MP+Ch SUP MP MP+Ch
A
A/CR
B
B/CR
C
C/CR
37.6
36.7
37.0
36.0
36.4
35.1
47.0 50.9
45.9 49.4
46.1 50.1
45.1 48.5
42.9 50.1
41,9 48.0
17.2
16.9
17.0
16.6
16.9
16.4
19.6
19.2
19.2
18.9
18.5
18.1
20.7
20.1
20.4
19.7
20.4
19.6
Results of baseline analysis assume no costs for complications from
supportive therapy, triple costs for MP strategy compared to the
conventional steroid treatment, and additional triple costs with MP+Ch
compared to MP (that is, 9 times compared to the conventional steroid
treatment). Definitions are in Table 2.
range 12.5 to 13.7) compared to supportive strategy, and more
than three years (average 4.7, range 3.4 to 7.2) compared to MP.
The difference in QALY with MP compared to supportive
strategy was more than 6.5 years (average 8.4, range 6.5 to 9.4).
The best LE of a 60-year-old nephrotic patient, fixed at 22.3
years, will decrease to an average of 16.8 QALY with support-
ive therapy, to 18.9 QALY with MP alone and to 20.1 QALY
with MP+Ch therapy. The difference in QALY with MP+Ch
compared to supportive strategy was more than three years
(average 3.3, range 3.1 to 3.5), and more than nine months
(average 1.2, range 0.8 to 1.9 years) compared to MP. The
difference in QALY with MP compared to supportive strategy
was more than 1.5 years (average 2.1, range 1.6 to 2.4).
In relative terms, treatment with MP+Ch in both ages
allowed an average 63% (range 60 to 66%) LE recovery, of
which 64% was achievable with MP alone, thus yielding 36%
superiority of MP+Ch versus MP strategy.
Discussion
Decision analysis was used to compare three different treat-
ment strategies in homogeneous patients from two Italian
controlled trials [3, 4]. In these studies, all patients came from
the same geographical area and were enrolled with the same
selection criteria, so that the groups were balanced in renal
function, duration of disease, histological findings of glomeru-
lar, interstitial, and vascular lesions, and blood pressure distri-
bution. The only difference was a lower proteinuria in the
untreated group compared to MP and MP+Ch groups (Table 1).
Thirty-nine untreated patients, 47 treated with MP and 87
treated with MP+Ch (42 from the first, and 45 from the second
trial) were analyzed with the unique advantage of comparing
patients treated not only with the same dosage and protocol of
MP and MP+Ch, but also given the same dosage of steroids in
both MP and MP+Ch groups. As a group, these patients could
be classified "patients with a variable course," since they were
neither high-risk nor low-risk patients according to the current
prognostic markers [14, 21—23]. At present, for the variable
course patient, many clinicians only use supportive therapy,
while giving immunosuppressive treatment for those with dete-
riorating renal function [14—19, 23—27] or massive and persistent
proteinuria [24]. However, since drugs, dosages, operative
definitions of outcomes, treatment schedules and duration are
not uniform in the literature, it is impossible to reach the
required power in comparing different strategies even by meta-
analysis [1—4, 16—18, 23, 25, 27—29].
The most important unresolved question even for decision
analysis is the prognosis of untreated patients. Authors who
recently tried summing-up all available data in the literature on
IMN found inconsistent estimates of outcomes with supportive
therapy [25, 29]. The rate of NS remission ranged from 16% of
patients, with a 95% confidence interval (CI) of 9—25% to 55%
(CI 45 to 55%). The progression to RF ranged from 24% (CI 16
to 34%) to 55% (CI 45 to 56%). All these (interval) estimates do
not significantly differ from those used in our analysis (Table 2).
Moreover, the highest probability of remission (55%) is lower
than our lowest threshold values, obtained assuming better
results with the supportive therapy compared to MP (56%) or to
MP+Ch (72%) (Table 3). The probabilities of progression to RF
used in our analysis are also very close to those estimated by
Pei, Cattran and Greenwood [24] for patients with proteinuria of
4 to 6 g/day and persistent for more than six months, namely 44
to 54%. Recently, the outcome of 100 patients with IMN, who
received only symptomatic therapy and were from the same
part of Italy of the two Italian trials, has been reported by
Schieppati et al [30]. Among the 37 patients followed for five
years, 13 (35%) had initial proteinuna in the range 2 to 3.5
glday, 11 out of 37 patients, or 30% (CI 16 to 47%) had at least
a doubling of initial serum creatinine, and 6 of these 11(55%)
required dialysis after five years of supportive therapy. Thus,
the true outcome, a reduced renal function, did not significantly
differ from our estimates. The reported higher rate of remission
(65%; CI 47 to 80%) is difficult to compare with that of our
nephrotic controls, since the group studied by Schieppati et al
included 35% patients with non-nephrotic proteinuria [30].
However, in their decision analysis, Levey et al [6] assumed
a probability of 40% remission with supportive therapy and 45%
progression to RF. Both values are in the order of our estimates
(Table 2).
What are the eventual and quantitative advantages of treating
the patients with variable course of IMN? Our decision analysis
indicated that the LE of a representative 40-year-old nephrotic
patient with IMN and normal renal function would decrease
from 36.4 to 25.2 QALY, or by 11.2 years, if treated only by
supportive therapy. Following a six month treatment with
MP+Ch, LE would only decrease from 36.4 to 32.4 QALY,
with an average recovery of 7.2 QALY, or 64%, compared to
supportive therapy. If treatment consisted of six months of MP
alone, the recovery was 4.6 QALY, or 64% of the maximal
recovery, achievable with MP+Ch. Therefore, the advantage of
MP+Ch over MP would be of 2.6 QALY, or in the order of 36%
(Table 2). Similar results in terms of percent of QALY apply to
younger and older patients. Of course, in absolute terms the
advantage of MP+Ch would be greater for a 20-year old patient
with an average gain of 13.0 QALY with MP+Ch and 8.3 with
MP compared with supportive treatment. In a 60-year-old
patient the advantage of MP+Ch was estimated at 3.3 QALY
compared to supportive strategy, of which 2.1 QALY was
achievable with MP (Table 4). Therefore, the analysis indicated
the superiority of the immunosuppressive treatment over the
supportive therapy for patients in the 20 to 60 age groups, with
a difference in expected survival greater than the minimal
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difference of 0.5 QALY. The analysis also indicated that the
decision would progressively become a toss-up over 60 years.
However, the extension to older patients of either the baseline
assumptions or outcomes observed in adults, are still to be
proven.
We are confident on the security of the baseline assumptions
for adult patients, since the results were obtained assuming no
risk for supportive therapy and high risk both for MP (death rate
0.3%, non-fatal complications 15%) and for MP+Ch (death rate
0.9%, non-fatal complications 45%). The risk assumed for MP is
considerably greater than the risk of death of 0.1% and of
non-fatal complication of 5% fixed by Kassirer [5] and Levey et
al [6], with a two month treatment with oral prednisone, and of
that reported with pulse steroid [31]. The risks for both MP and
MP+Ch are also far greater than the rates of death and non-fatal
complications actually observed in the two Italian trials [3, 4].
At present no definite data exist in literature concerning the
relative safety of chlorambucil-based regimens, especially if
limited to a cumulative period of three months as in the Italian
trials [9, 13—19, 321. Side effects such as oncogenicity and
gonadal toxicity could rise with increments of cumulative
dosage, and the risk of toxic effects on bone marrow could be
unpredictably higher in the elderly, and in those with renal
failure [12, 14, 16].
In the sensitivity and threshold analyses, in order to achieve
the expected survival of MP+Ch with only supportive therapy,
we had to assume a probability of spontaneous remission far
greater than 95% confidence limit of those observed and of
those reported in literature, even when angiotensin converting
enzyme inhibitors, and non-steroidal antiinflammatory drugs
were used [1, 2, 5, 6, 14, 24—26, 28, 29, 33]. On the other hand,
to bring the expected survival with MP+Ch down to that of
supportive therapy, a probability of NS remission following
MP+Ch must be assumed to be lower than 95% confidence
limits. Alternatively, a probability of progression to RF out of
the 95% confidence intervals had to be assumed. In other
words, the expected survival with MP+Ch was far greater than
the most favorable, reasonable prediction of outcomes with
supportive therapy. More inequalities of the threshold analysis
were also reached by the MP compared to the supportive
strategy.
Thus, the decision analysis demonstrated that MP+Ch treat-
ment could restore 64% LE of a representative nephrotic
patient, of which 64% could be obtained by a treatment with MP
based on high-dose intravenous MP pulses followed by alter-
nate-day oral MP. Evaluating the risk and efficacy of the two
treatments on a quantitative basis by sensitivity and threshold
analyses, to offset the 36% advantage in expected survival with
MP+Ch versus MP, we had to assume a death rate higher than
6% or, alternatively, a combined threshold assuming that all
patients treated with MP+Ch undergo either fatal (5% vs. 0.3%
with MP alone) or non-fatal complications (95% vs. 15% with
MP alone), and that costs for non-fatal complications be set at
one year versus two weeks with MP alone. This combined
threshold can be used as a tool in conveying risk-efficacy
assessment to the individual 40-year-old patient. One will have
on average 2.6 more QALY survival, being treated with
MP+Ch instead of MP, provided one is willing to pay a cost in
QALY. The trade-off for the greater effectiveness with MP+Ch
is up to one year versus two weeks in non-fatal complications,
with a death risk no greater than 5% versus 0.3%. The thresh-
olds we found for risks were apparently higher than the most
pessimistic prediction. Another study [291, considering the
literature (before the last Italian trial) and using a simple scoring
assignment of utility, found 0.72, 0.80, and 0.89 scores over a
three-year follow-up, and 0.75, 0.78, 0.88 scores over a five-
year follow-up for supportive, oral steroid, and MP+Ch strat-
egies, respectively. In other words, they found a 61% to 52%
score recovery with MP+Ch compared to the supportive strat-
egies.
Since reduction of proteinuna in the long-term may result in
a more favorable outcome [6, 8, 9, 14, 24, 34] in addition to
symptomatic relief of the nephrotic syndrome, and also to
reduction of the risk for morbidity and mortality [35—37],
effective protocols such as those including six months with
MP+Ch must be considered [37, 38]. Moreover, as recently
reviewed by Glassock [14], glucocorticoids are probably effec-
tive if given orally at higher dosages and over more prolonged
periods than conventional therapies. Intravenous followed by
oral glucocorticoids are also probably more effective than oral
treatment alone, even in patients with abnormal renal function
and heavy proteinuna [14, 27].
In conclusion, we are aware that estimates of the outcomes of
available trials are based on a limited sample size, but we are
confident of the consistency of our decision analysis, where
indications can be applied to patients with comparable clinical
and histological patterns of IMN. Consequently, for obtaining
freedom from NS we are justified in treatment with MP for six
months, if together with the individual patient we consider its
moderate side effects a suitable trade-off for a five QALY longer
survival. We will treat with MP+Ch therapy if we believe that
a further increase in at least two QALY pays for the reported
more non-fatal complications, being aware that only an absurd
increase in death rate, over 5%, could offset the associated
longer survival. Alternatively, one may opt for supportive
therapy, knowing that a QALY of seven years survival would
be lost for a 40-year-old patient.
Reprint request to Prof. A. Piccoli, Istituto di Medicina Interna,
Cattedra di Nefrologia, Via Giustiniani, 2, 1-35128 Padova, Italy.
Appendix
As shown in Figure 1, in the analysis it is assumed that:
I) patients with NS are at risk for early complications of proteinuria and
for progressive RF;
2) patients who achieve a partial or complete remission within two
years of the onset do not have long-term complications of NS and do
not develop RF;
3) the frequency of remissions, and progression to RF differs according
to the treatment given.
Four outcomes of NS are defined by these assumptions, with increasing
QALY values:
a) early death due to fatal complications either from NS or treatment;
b) persistence of NS with subsequent development of RF;
c) persistence of NS with maintenance of stable renal function;
d) sustained remission of proteinuna within the first 2 years with
maintenance of stable renal function thereafter.
The baseline values for adjustments to LE and the equations for
utility expressions of QALY for the outcomes are as follows:
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Remission, QALY = LE - C — CNS
Persistent NS, QALY = LE X LTQNS — C — CNS
Renal Failure, QALY = SRF x LTQNS + LERF X LTQRF — CEX
— CNS
Death, QALY = 0 years
where, in baseline analysis, values for variables involved in QALY
calculation are zero if not occurring in the pathway reaching the
considered outcome, otherwise:
LE = 36.4 years, age-adjusted normal life expectancy
CRX = 2 weeks (0.04 QALY), short-term cost for complications
from MP therapy, and 6 weeks (0.12 QALY) for compli-
cations from MP+Ch
= 2 weeks (0.04 QALY), short-term cost for complications
from NS
= 10 years, survival until terminal RF develops
= 0.9, long-term quality adjustment for NS
= 9.7 years, LE at the onset of terminal RF
= 0.75, long-term quality adjustment for terminal RF
Costs are non-monetary penalties for the quality of life.
Probability of short-term complications of the NS:
P(fatal complications) = 0.3%
P(non-fatal complications) = 5.0%.
Probability of short-term complications from treatment:
P(fatal complications) = 0% with supportive, 0.3% with MP, 0.9%
with MP+Ch therapy
P(non-fatal complicatins) = 0% with supportive, 15% with MP,
45% with MP+Ch therapy.
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